They clarify the crucial differences between NETs and NECs, explain why accurate classification and rapid treatment are essential, and highlight current and emerging therapeutic approaches, including DLL3-targeted therapies.  

Through both HCP and patient-centred perspectives, the conversation addresses real-world challenges, the importance of support networks, and the growing sense of hope for people affected by this difficult disease. 

Key clinical takeaways:  

• Unlike NETs, EP-NECs are poorly differentiated, high-grade, aggressive, and fast-growing cancers, with a need for more effective treatments

• While there remains a medical need for effective treatment of EP-NECs, clinical studies with DLL3-targeted agents show promise 

• Accessing a support network can provide emotional reinforcement and information for patients and their care partners 

You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/net-connect/programmes/ep-nec-diagnosis-treatment-support/?media=0 

Or watch on YouTube: https://youtu.be/nfng2s3jSw8 

Follow us on social media: 

LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true  

X:https://x.com/net_connectinfo 

This podcast is supported by an Independent Education Grant from Boehringer Ingelheim.

This podcast is developed by cor2ed.com 

Published in November 2025 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

In this podcast moderated by the Oncology Brothers, Drs Rohit and Rahul Gosain are joined by medical oncologist Dr Heloisa Soares and nuclear medicine physician Prof. Ken Herrmann to explore the evolving role of targeted radioligand therapy in NETs. 

As the conversation unfolds, the experts discuss evidence from recent studies, including the COMPETE trial, share practical insights on multidisciplinary decision-making, and highlight future directions such as the potential for first-line treatment with radioligand therapy. 

Key clinical takeaways:  

• Pair the right patient with the right treatment using an understanding of the key clinical studies 

• The role of PRRT as a very effective 2nd-line treatment was consolidated by the COMPETE study data  

• The best outcomes are achieved through multi-disciplinary collaborations that include the patient 

Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website, where you can also download the accompanying transcript and infographic: https://cor2ed.com/net-connect/programmes/targeted-radiopharmaceutical-treatment-nets/?media=0

Follow us on social media: 

LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true  

X: https://x.com/net_connectinfo  

This content is intended for healthcare professionals only. 

This podcast is supported by an Independent Education Grant from ITM.  

This podcast is developed by cor2ed.com 

Published September 2025 

Gain valuable knowledge on identifying and managing this rare condition, with practical takeaways for clinical practice.  

Key clinical takeaways:  

• Growth hormone resistance can range from severe IGF-1 deficiency, like in classic Laron syndrome, to milder mutations in the same receptor. There can also be mutations in other parts of the signalling pathway 

• Patients with SPIGFD have low IGF-1 levels resulting from growth hormone resistance or insensitivity, rather than deficiency, as they produce sufficient or even high levels of growth hormone without secondary causes of growth failure 

• Laron syndrome, a classic form of SPIGFD, is characterised by severe short stature and distinct features such as spontaneous hypoglycemia, mid-face hypoplasia, frontal bossing, a high-pitched voice, and underdeveloped genitalia in boys 

• Early and accurate diagnosis of SPIGFD is crucial for effective management, as growth hormone therapy is ineffective for these patients; recognising the distinction between severe and less severe IGF-1 deficiency, as well as primary versus secondary causes, ensures appropriate treatment to ensure optimal outcomes 

• Recombinant IGF-1 therapy is indicated for patients with SPIGFD. Healthcare professionals must monitor for adverse events such as hypoglycemia and potential malignancies 

Watch the experts in conversation in the full video or get the 5-minute highlights: https://cor2ed.com/pe-connect/programmes/short-stature-spigfd/

Follow us on social media: 

LinkedIn: https://www.linkedin.com/showcase/pe-connect/

X: https://x.com/peconnectinfo

This content is intended for healthcare professionals only.  

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Education Grant from Ipsen 

This podcast is developed by cor2ed.com 

Published December 2024 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

The speakers discuss different treatment settings, including home vs hospital-based injections, as well as the importance of individualising treatment decisions, as there is often no standard therapy for patients with NETs. Finally, they look at some of the studies reporting patient preferences, and how the data can be used to inform patient decisions. 

Prefer to watch and listen? 
Watch the video and download the full transcript on the COR2ED website https://cor2ed.com/net-connect/programmes/net-shared-decision-making/?media=1 

Watch the full video on YouTube https://youtu.be/2JYuPhc2jHg 

Watch the highlights video on YouTube – https://www.youtube.com/watch?v=pPMVLjPLv8k

Follow us on social media 

LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect  

X: https://x.com/net_connectinfo  

This content is intended for healthcare professionals only. 

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Medical Education Grant from Ipsen 

This podcast is developed by cor2ed.com 

Published July 2024 

The speakers share their real-life experiences of what makes a good consultation, from the perspectives of both a patient and a physician. They also explore the importance of support networks, individualising treatment, and the impact of NET and NET treatment options in daily life.  

NETs are complex, rare diseases. Optimal management and treatment requires early diagnosis, shared decision-making, and timely referral. Are you aware of how healthcare practitioners and patients can share decision- making? Or the recent data on how patients prefer to receive treatment?  

In this first episode of a two-part podcast series, Dr Mohid S Khan and NET patient Sally Jenkins discuss shared decision-making in NET consultations and ways to help the patient in their journey. 

Prefer to watch and listen? 
Watch the video and download the full transcript on the COR2ED website https://cor2ed.com/net-connect/programmes/net-shared-decision-making/

Watch the full video on YouTube https://youtu.be/YgqrEnSePWg

Watch the highlights video on YouTube – https://www.youtube.com/watch?v=pPMVLjPLv8k

Follow us on social media 

LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect  

X: https://x.com/net_connectinfo  

This content is intended for healthcare professionals only. 

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen 

This podcast is developed by cor2ed.com 

Published July 2024 

Prof. Martyn Caplin is Professor of Gastroenterology and GI Neuroendocrinology at the Royal Free Hospital and University College London, UK, he also leads The Royal Free London “European Neuroendocrine Tumour Society’s Centre of Excellence” and the UCL Academic Neuroendocrine Tumour Unit, which includes leading scientific and clinical research programmes into NETs. Prof. Rachel Riechelmann is a medical oncologist and clinical scientist focused on colorectal/anal cancers and NETs. Director of the Clinical Oncology Department, AC Camargo Cancer Center, in Sao Paulo, Brazil and is Head of the Neuroendocrine Tumors Reference Center. 

Prefer to watch as well as listen? 

Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/net-connect/programmes/regional-differences-neuroendocrine-tumours-nets-2/  

Or go to the video on YouTube: https://youtu.be/zd_JvUmIhFg 

We are pleased to share that this podcast is endorsed by the North American Neuroendocrine Tumor Society (NANETS). You can find out more about NANETS at https://nanets.net/  

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen. 

This podcast is developed by cor2ed.com

NETs are complex, rare diseases. Their optimal management and treatment requires early diagnosis, shared decision-making, and timely referral. The best possible patient journey is impacted by regional differences in management strategies, referral pathways, and availability of diagnostic modalities and treatments.. Are you aware of the epidemiology of NETs and current best practices for diagnosis, referral strategies, and treatment for NETs? Or how regional differences can impact these? In this first episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss regional differences in NET epidemiology, patient pathways, as well as look to future developments.  

Prof. Martyn Caplin is Professor of Gastroenterology and GI Neuroendocrinology at the Royal Free Hospital and University College London, UK, he also leads The Royal Free London “European Neuroendocrine Tumour Society’s Centre of Excellence” and the UCL Academic Neuroendocrine Tumour Unit, which includes leading scientific and clinical research programmes into NETs. Prof. Rachel Riechelmann is a medical oncologist and clinical scientist focused on colorectal/anal cancers and NETs. Director of the Clinical Oncology Department, AC Camargo Cancer Center, in Sao Paulo, Brazil and is Head of the Neuroendocrine Tumors Reference Center. 

Prefer to watch as well as listen? 

Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/net-connect/programmes/regional-differences-neuroendocrine-tumours-nets-1/  

Or go to the video on YouTube: https://youtu.be/6fKAxS4u-2o 

We are pleased to share that this podcast is endorsed by the North American Neuroendocrine Tumor Society (NANETS). You can find out more about NANETS at https://nanets.net/  

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen. 

This podcast is developed by cor2ed.com 

Join Prof. Helen Storr (Professor and Honorary Consultant in Paediatric Endocrinology at Queen Mary University, London and Barts Health Trust, London, UK) and Prof. Andrew Dauber (Chief of Endocrinology, Children's National Hospital. Washington, DC, USA) as they engage in a conversation about the diagnosis and management of patients with severe primary IGF-I deficiency. This is the second video podcast episode in a two-part series on patients with severe short stature.

Prefer to watch as well as listen?

Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/pe-connect/programmes/severe-primary-igfi-deficiency/

Or go to the video on YouTube: https://youtu.be/7sNGzJRzv7g

• This Podcast is endorsed by the Magic Foundation.Find out more on their website: https://www.magicfoundation.org/

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen. This podcast is developed by COR2ED.com

For children presenting with short stature, an early and correct diagnosis is essential to allow children to achieve their full growth potential with appropriate treatment. Listen as expert pediatric endocrinologists delve into these rare growth disorders.

Join Prof. Philippe Backeljauw (Professor at Cincinnati Children's Hospital Medical Center and the University of Cincinnati, Cincinnati, USA) and Prof. Dr. Joachim Woelfle (Chairman of Pediatrics, Director of the Department of Pediatric and Adolescent Medicine at the Friedrich Alexander University Erlangen, Germany) as they engage in a conversation regarding key challenges in the diagnosis and management of patients with short stature conditions.

The experts discuss the incidence of patients with GHD and severe primary IGF-I deficiency and how to differentiate these conditions based on clinical presentation as well as biochemical and genetic testing. The importance of taking a good medical history and physical examination is discussed, as well as various caveats related to biochemical and genetic testing. Regional differences in the diagnosis of these patients are covered as well as key challenges in the diagnosis and management. Finally, the experts discuss the different treatment options as well as the importance of ensuring caregivers are well-informed regarding the efficacy and safety of the respective treatments.

This is the first video podcast episode in a two-part series on patients with severe short stature.

Prefer to watch as well as listen?

Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/pe-connect/programmes/rare-growth-disorders-podcast/

Or go to the video on YouTube:

https://youtu.be/OfI3lZgjew0  

• This Podcast is endorsed by the Magic Foundation. Find out more on their website: https://www.magicfoundation.org/

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen. This podcast is developed by COR2ED.com

Join Prof. Cédric Hermans (Head of the Division of Haematology, the Hemostasis and Thrombosis Unit and the Hemophilia Center of the Saint-Luc University Hospital in Brussels, Belgium) and Prof. Miguel Escobar (Professor of Medicine and Pediatrics, University of Texas Health Science Center at Houston-McGovern Medical School and University of Texas M.D. Anderson Cancer Center Medical Director, Gulf States Hemophilia & Thrombophilia Center Houston, USA) as they engage in a conversation about the potential of gene and gene-modified cell therapies in rare diseases, and how early gene therapies have been implemented as a treatment approach for rare diseases, such as leber congenital amaurosis, spinal muscular atrophy, beta-thalassemia, adrenoleukodystrophy, and hemophilia.

The experts explore hemophilia as an example of how gene therapy has become a reality within rare diseases. They discuss why we need gene therapy for rare disease, what gene therapy and gene modified cell therapy is, and how this has become a reality in hemophilia, and look to the future of gene therapy for rare diseases. Finally they reflect on the importance of a multidisciplinary approach.

- Access information on the programme, the clinical takeaways, the flashcard and the transcript here https://cor2ed.com/hemostasis-connect/programmes/gene-therapy-rare-diseases/

Find out about the experts Prof Cedric Hermans and Prof. Miguel Escobar. 

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from The American Society of Gene + Cell Therapy and Pfizer.

Their discussion covers the relationship between initial symptoms and disease trajectory, the association of biochemical control and outcomes in PBC, and the impact and assessment of patient reported outcomes.

Their discussion focuses on cancer risk associated with PBC; liver stiffness and prognosis; and outcomes and response prediction in second-line therapy.

They share their clinical experience and their own clinical practice, based on data from key studies including NETTER-1, CLARINET FORTE, and REMINET, as well as relevant retrospective analyses. Prof. Martyn Caplin is Professor of Gastroenterology and GI Neuroendocrinology at the Royal Free Hospital and University College London, London, UK. Dr Aman Chauhan is a Medical Oncologist and Director of NET Theranostics at the University of Kentucky Markey Cancer Center, Kentucky, USA.

The experts opened the podcast with the importance of engaging diverse patient communities. Independent of geography, patients should be educated about their condition and prepared for clinical trial participation; advocacy groups play a central role in this engagement. The experts then discussed outcomes of the IMPACT survey in OI (osteogenesis imperfecta), whose extensive database (66 countries, >2000 participants) offers meaningful insights into the clinical, humanistic and economic challenges faced by OI patients around the world. Looking to advances in pre-clinical research, the experts reviewed data on nanoparticle-mediated delivery of small interfering RNA (siRNA) to targeted mutation sites, tested in an animal model of autosomal dominant osteopetrosis. As the experts note, patient communities struggle with lengthy research and development timelines for novel therapies; therefore, it’s important for advocates to keep communities informed about ongoing efforts.

Prof. Rush opens with detailed information on fibrodysplasia ossificans progressiva (FOP): symptoms of this severe congenital condition include permanent heterotopic ossifications preceded by painful soft tissue swelling. Nearly all patients have the same ACVR1 receptor variant, and Prof. Rush shares therapy options for the disease. He then offers insights on hypochondroplasia (HCH), a developmental disorder caused by a defect in the FGFR3 gene. An animal model for HCH has been developed, in which infigratinib, a selective FGFR tyrosine kinase inhibitor, shows positive effects on growth as well as proportion. He then describes a clinical study in osteogenesis imperfects (OI), in which allogenic transplantation of fetal liver-derived mesenchymal stem cells was tested in children with type III and type IV OI. While increased bone density and height were observed, Prof. Rush cautions that both the number of study participants and the study duration were low. He closes the podcast with personal insights from the in-person Annual Meeting, including opportunities for engagement and exchange at “Meet the Professor” sessions.

Opening with an overview of ongoing clinical research in several rare bone diseases, Prof. Teti highlights the importance of preparing clinicians for unexpected adverse events. Notably, therapies used in the context of rare bone diseases can cause adverse events not seen if a common bone disease was treated. For osteogenesis imperfecta, she discusses a novel treatment based on umbilical cord mesenchymal stem cells. A safety study in 18 paediatric patients – three of whom received a pre-natal injection – is awaiting completion by the end of 2023. Initial safety data suggests that multiple stem cell transplantations in children with this disease is safe. Prof. Teti emphasizes the impact of achondroplasia, the most common rare bone disease, and one for which new treatments are also in development. Pharmacological treatment aims to reduce activity of the pathogenic, overactive variant of FGFR3 which causes the disease. She is confident that a treatment will be found that, at minimum, enhances quality of life in patients. Prof. Teti concludes with a review of the highly collaborative spirit of the Rare Diseases Symposium, emphasizing that patient well-being must be the driving force of research.

The two experts discuss how to improve PBCdiagnosis, the importance of listening to patient needs when considering PBC treatment options, considerations for treating PBC-related symptoms, differences in PBC diagnosis and treatment guidelines between Europe and the US, and what's coming next for this rare liver disease. 

This is the final episode in a series of four podcasts, in this episode Dr Eekhoff and Dr Rush discuss their rare bone disease highlights from the meeting.

 This is the third episode in a series of four podcasts. In this episode Charlene Waldman (RBD Alliance) and Inês Alves (European Rare Bone Forum) discuss their highlights.

This is the second in a series of four podcasts. In this episode Dr Oliver Semler has selected and discusses his highlights.

This is the first episode in a series of four podcasts, in this episode Dr Mughal and Dr Javaid discuss their highlights.